Amanda C. Guidon

Harvard University — United States

Medicine · Health Sciences

26h-index3.5kcitations89works5.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Myasthenia Gravis and Thymoma(43), Cancer Immunotherapy and Biomarkers(20), Peripheral Neuropathies and Disorders(20), Parkinson's Disease and Spinal Disorders(9), Brain Metastases and Treatment(8)

Publications86 total

Development and Feasibility Assessment of a Multimodal Digital Health Technology for Remote Monitoring of Symptoms in Myasthenia Gravis
Digital Biomarkers·2025Open Access
COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)
UNC Libraries·2025Open Access
Advancing Remote Monitoring of Myasthenia Gravis Symptoms through Digital Health Technology
Neurotherapeutics·2025Open Access
Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic
UNC Libraries·2025Open Access
Wearable-based Remote Monitoring of Disease Symptoms in Myasthenia Gravis (P1-11.023)
Neurology·2025
A Multi-modal Digital Health Technology for Remote Monitoring of Symptoms in Myasthenia Gravis (P1-11.024)
Neurology·2025
Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors
Journal for ImmunoTherapy of Cancer·2025· 12 citedOpen Access
Application of digital tools and artificial intelligence in the Myasthenia Gravis Core Examination
Frontiers in Neurology·2024· 10 citedOpen Access
Peripheral nervous system immune-related adverse events due to checkpoint inhibition
Nature Reviews Neurology·2024· 28 cited
Application of Digital Tools and Artificial Intelligence to the Myasthenia Gravis Core Examination
2024· 4 citedOpen Access
Trends and Disparities in the Utilization of Thymectomy for Myasthenia Gravis in the United States
Neurology Clinical Practice·2024· 6 citedOpen Access
Treatment Fluctuations in Patients with Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis on Maintenance Ravulizumab Treatment (P10-11.001)
Neurology·2024· 1 cited
Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes
The Lancet Neurology·2023· 93 cited
EP11.03-02 Characterizing Neurologic Immune-related Adverse Events Using Consensus Disease Definitions
Journal of Thoracic Oncology·2023Open Access
The Neuromuscular Portal and Match
Neurology Education·2023· 5 citedOpen Access
Application of a Validated Algorithm to Identify and Describe Contemporary Epidemiology of Privately Insured Myasthenia Gravis Patients in the United States (N6.002)
Neurology·2023
BioDigit MG: A Pilot Study Examining a Digital Technology for Quantitative Assessment and Remote Monitoring of Myasthenia Gravis (P7-8.005)
Neurology·2023
Implementation of a myasthenia gravis <scp>drug‐disease</scp> interaction clinical decision support tool reduces prescribing of <scp><b>h</b>igh‐risk</scp> medications
Muscle & Nerve·2023· 1 cited
Safety and outcomes of eculizumab for acetylcholine receptor‐positive generalized myasthenia gravis in clinical practice
Muscle & Nerve·2022· 7 cited
Factors associated with utilization of telemedicine during the COVID-19 pandemic among patients with myasthenia gravis: A retrospective regional cohort study (P11-13.009)
Neurology·2022
page 1 of 5Next →

Frequent Co-authors

Kerry L. Reynolds(16), Justine V. Cohen(10), Tomas G. Neilan(10), Ryan J. Sullivan(9), Michael Dougan(9), Jeffrey T. Guptill(9), Richard J. Nowak(9), Meghan E. Sise(9), Vern C. Juel(8), James F. Howard(8), Henry J. Kaminski(8), Michael K. Hehir(7), Anthony A. Amato(6), Meghan J. Mooradian(6), Leyre Zubiri(6), Steven T. Chen(6), Sara Schoenfeld(6), William S. David(5), Molly Thomas(5), Aditya Bardia(5)